Nature Communications | Phase 3 Clinical Trial Results of Disitamab Vedotin versus Lapatinib plus Capecitabine for HER2-Positive Breast Cancer with Liver Metastases

This study provides a new therapeutic strategy for patients with HER2-positive breast cancer and liver metastases, suggesting that the construction of relevant disease models must prioritize the impact of the liver microenvironment on drug metabolism and bystander effects.

 

Literature Overview

This article, titled "Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial," published in Nature Communications, systematically explores the efficacy and safety of the novel antibody-drug conjugate (ADC) Disitamab vedotin (DV) compared to lapatinib plus capecitabine (L+C) in patients with HER2-positive breast cancer and liver metastases who have previously received trastuzumab and taxanes. Building on positive signals from prior Phase 2 data, this prospective randomized Phase 3 trial specifically targeted this subgroup with a poor prognosis, confirming the significant advantage of DV in extending progression-free survival.

Background Knowledge

Breast cancer liver metastases (BCLM) account for approximately 45% of all HER2-positive advanced cases, with a median overall survival of only 2 years, which is far lower than that of general advanced patients, representing a major clinical challenge. Although HER2-targeted therapies have made progress, existing standard treatments carry risks: T-DXd is associated with interstitial lung disease, T-DM1 frequently causes severe thrombocytopenia in Asian populations, and the lapatinib plus capecitabine regimen is often accompanied by severe gastrointestinal toxicity. Furthermore, HER2 expression levels in liver metastases may be higher than in primary tumors, and liver-specific protease activity may accelerate drug release, providing a theoretical entry point for developing HER2-targeted drugs optimized for the liver microenvironment. As a novel ADC, DV features a cleavable linker and a membrane-permeable toxin (MMAE), endowing it with unique bystander killing effects, which hold promise for addressing the insufficient efficacy of traditional therapies in the liver metastasis microenvironment.

 

 

Research Methods and Experiments

This study employed a prospective, open-label, multicenter randomized design, assigning 104 eligible patients with HER2-positive liver metastases in a 1:1 ratio to either the DV group or the L+C group. Key experimental evidence was derived from the assessment of tumor progression by a Blinded Independent Review Committee (BIRC). The study meticulously recorded baseline patient characteristics, including hormone receptor status, number of prior treatment lines, and metastatic sites, to ensure balance between the two groups. Progression-free survival (PFS) was analyzed using the Kaplan-Meier method, and hazard ratios (HR) were calculated using a stratified Cox proportional hazards model, alongside subgroup analyses to verify the consistency of efficacy. Safety assessments covered all treatment-related adverse events (TRAEs), with particular attention paid to liver biochemical indicators, hematologic toxicity, and peripheral neuropathy.

Key Conclusions and Perspectives

• The median PFS in the DV group was significantly superior to that in the L+C group (9.9 months vs. 4.9 months), with an HR of 0.56 and P=0.01, indicating that DV significantly delays tumor progression in HER2-positive liver metastases and provides a new time window reference for subsequent clinical monitoring.
• The objective response rate (ORR) and disease control rate (DCR) in the DV group were both higher than in the control group. Subgroup analysis showed that DV provided benefits regardless of hormone receptor status or prior pertuzumab use, suggesting broad applicability in drug development.
• In terms of safety, no cases of interstitial lung disease or grade 3 or higher thrombocytopenia occurred in the DV group. The main adverse events were elevated transaminases and peripheral neuropathy, offering an alternative to T-DXd and T-DM1 for patients with underlying lung diseases or risks of thrombocytopenia.
• The study confirmed the effectiveness of DV's unique bystander killing effect in the liver metastasis microenvironment, suggesting that future disease modeling should incorporate liver-specific protease activity and tumor heterogeneity factors to more accurately predict the in vivo distribution and efficacy of ADC drugs.

Research Significance and Prospects

This study not only establishes DV as a new standard for second-line treatment of HER2-positive liver metastases but also reveals the clinical value of ADC drugs optimized for the liver microenvironment from a mechanistic perspective. For drug development, the success of DV validates the advantage of combining cleavable linkers with membrane-permeable toxins in solid tumor metastases. At the level of clinical monitoring, physicians can prioritize the DV regimen for patients with impaired liver function or those unable to tolerate pulmonary toxicity based on these findings. Furthermore, the study emphasizes the importance of stratified treatment for specific metastatic sites (such as the liver), promoting the refinement of precision treatment strategies for breast cancer.

 

 

Conclusion

The success of the RC48-C006 Phase 3 clinical trial marks a major breakthrough in the field of treating HER2-positive breast cancer with liver metastases. Through a rigorous randomized controlled design, this study confirmed the significant advantage of Disitamab vedotin in extending progression-free survival for patients, with a safety profile superior to existing standard therapies. From a translational perspective spanning from laboratory to clinic, this finding not only fills the gap in targeted therapies optimized for the liver microenvironment but also provides critical treatment options for patients with specific comorbidities. In the future, diagnostic and treatment protocols established based on this study will significantly improve the care standards for related diseases, driving breast cancer treatment toward greater precision and safety, and laying a solid foundation for improving survival outcomes in advanced patients.

 

Jiayu Wang, Quchang Ouyang, Weimin Xie, Jianmin Fang, and Binghe Xu. Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial. Nature Communications.